ライフサイエンスコーパス: lower urinary tract

1 clusively expressed in the epithelium of the lower urinary tract).

2 ted reconstructive urological surgery on the lower urinary tract.

3 cord can promote functional recovery of the lower urinary tract.

4 yotonic discharges in skeletal muscle of the lower urinary tract.

5 omparable to transplantation into the normal lower urinary tract.

6 a role in functional neuroregulation of the lower urinary tract.

7 functions of respective target organs in the lower urinary tract.

8 ction, there were 8 infectious events of the lower urinary tract.

9 ted with complex pathology in the kidney and lower urinary tract.

10 ic duct and cloaca, analogs of the mammalian lower urinary tract.

11 s to deeper tissue and persist better in the lower urinary tract.

12 on, specifically, chemical irritation of the lower urinary tract.

13 h heterogeneous origins and functions of the lower urinary tract.

14 atients had one or more abnormalities of the lower urinary tract.

15 part of pretransplantation assessment of the lower urinary tract.

16 t obstruction or congenital anomalies of the lower urinary tract.

17 neuromodulation, to treat pathologies of the lower urinary tract.

18 both molecules in neural development in the lower urinary tract.

19 tic differences between TCC in the upper and lower urinary tracts.

20 to urologic diseases affecting the upper and lower urinary tracts.

21 performed on all children with dysfunctional lower urinary tracts.

22 ts were performed in 61 patients with normal lower urinary tracts.

23 tional cell carcinoma (TCC) of the upper and lower urinary tracts.

24 re more likely to have a foreign body in the lower urinary tract (48% versus 30% overall).

25 y increased 66%, suggesting sensitization of lower urinary tract afferents.

26 on regulates state-dependent reflexes in the lower urinary tract and contribute to our understanding

27 l to understanding the neural control of the lower urinary tract and how dysfunction arises in diseas

28 performed in 20 children with dysfunctional lower urinary tracts and 61 transplants were performed i

29 ry and digestive cancers and tumors from the lower urinary tract, and below 20% for the remaining TRC

30 ering the subjects of renal transplantation, lower urinary tract anomalies, and bladder reconstructio

31 Abnormalities of the lower urinary tract are common in children with unilater

32 When TCC of the upper and lower urinary tracts are compared, MSI-H is more frequen

33 neural folds and protein localization in the lower urinary tract at critical periods for forebrain di

34 ts to remain committed to rehabilitating the lower urinary tract avoiding palliative maneuvers and of

35 d to congenital anomalies of kidneys and the lower urinary tract (CAKUT) are poorly understood.

36 ally important in health and ailments of the lower urinary tract cause high pathological burden.

37 hat AS and EBS do not contribute to upper or lower urinary tract colonization by E. faecalis and that

38 The upper and lower urinary tract compartments form independently, con

39 activity and contributes to pathogenesis of lower urinary tract defects in human infants.

40 imarily a research tool in the evaluation of lower urinary tract disorders in the female; however, a

41 Lower urinary tract disorders such as overactive bladder

42 ways may reveal novel targets for therapy of lower urinary tract disorders such as overactive bladder

43 al calculi, lower urinary calculi, and other lower urinary tract disorders.

44 pefully lead to more effective treatments of lower urinary tract disorders.

45 be a target for pharmacological treatment of lower urinary tract disorders.

46 he diagnosis and management of patients with lower urinary tract disorders.

47 key component of the clinical evaluation of lower urinary tract dysfunction and include filling cyst

48 The cause of lower urinary tract dysfunction included posterior ureth

49 common neurological disease associated with lower urinary tract dysfunction is important for urologi

50 will involve pelvic organ prolapse (POP) and lower urinary tract dysfunction, are expected to reach e

51 en associated with undiagnosed and untreated lower urinary tract dysfunction, emphasizing the importa

52 toxin as a treatment modality for those with lower urinary tract dysfunction, especially for those wi

53 a gold standard in patients with neurogenic lower urinary tract dysfunction, female bladder outlet o

54 jury could prevent development of neurogenic lower urinary tract dysfunction, in particular detrusor

55 SCI could prevent development of neurogenic lower urinary tract dysfunction.

56 toxin has been investigated for treatment of lower urinary tract dysfunction.

57 ulinum toxin is awaiting approval for use in lower urinary tract dysfunction.

58 he vaginal wall, paraurethral pathology, and lower urinary tract dysfunction.

59 first causal treatment option for neurogenic lower urinary tract dysfunction.

60 Apart from the lower urinary tract dysfunctions, the proposed technolog

61 ract to evaluate the results of contemporary lower urinary tract evaluation and management on graft s

62 owever, 35% of patients with a dysfunctional lower urinary tract experienced urologic complications.

63 Prevention of lower urinary tract fistula requires improvement in the

64 nimal-access procedures in reconstruction of lower urinary tract fistulas focusing on the bladder.

65 rious therapeutic approaches for normalizing lower urinary tract function after spinal cord injury.

66 complication rates, careful surveillance of lower urinary tract function by urodynamic evaluation is

67 bladder urothelium and their contribution to lower urinary tract function in the rat.

68 e complex impact of pelvic organ prolapse on lower urinary tract function is crucial to successful ma

69 e combined with the goal of restoring normal lower urinary tract function.

70 junction valve mechanism as well as aberrant lower urinary tract function.

71 sacral spinal nuclei involved in controlling lower urinary tract functions, including micturition, we

72 Foreign body in the lower urinary tract has a low incidence.

73 neurons innervating different regions of the lower urinary tract have different histochemical and ele

74 ctional cross-sensitization of the colon and lower urinary tract in a novel experimental model.

75 ccurrence of congenital abnormalities of the lower urinary tract in humans, the molecular, cellular a

76 erformed analysis of Y1015F mutant upper and lower urinary tracts in mice to delineate its molecular

77 Much of the lower urinary tract, including the bladder, is lined by

78 atory marker most predictive of upper versus lower urinary tract infection and renal scarring.

79 vent rates were similar between groups, with lower urinary tract infection incidence in the SGLT2i gr

80 had pyuria and a diagnosis of a complicated lower-urinary-tract infection or pyelonephritis were ran

81 Lower urinary tract infections are among the most common

82 n the treatment of patients with complicated lower-urinary-tract infections or pyelonephritis.

83 se levofloxacin in patients with complicated lower-urinary-tract infections or pyelonephritis.

84 key for the successful management of female lower urinary tract injuries associated with lower abdom

85 importance of diagnosing and managing female lower urinary tract injuries, both of the bladder and th

86 juries are often associated with devastating lower urinary tract injuries.

87 nsion-free vaginal tape has a higher rate of lower urinary tract injury and voiding dysfunction when

88 nergic muscarinic system can be activated by lower urinary tract irritation to suppress visceral noci

89 KEY POINTS: The lower urinary tract is regulated by reflexes responsible

90 Renal transplantation into the abnormal lower urinary tract is successful but requires careful p

91 fferent pathways play in the function of the lower urinary tract is the focus of much current researc

92 ntracts smooth muscle cells within the human lower urinary tract (LUT) (bladder neck, prostate, and u

93 The lower urinary tract (LUT) and micturition reflexes are s

94 vestigated pudendal nerve innervation of the lower urinary tract (LUT) by employing anatomical (Sihle

95 Lower urinary tract (LUT) dysfunction is a common sequel

96 Chemical irritation of the lower urinary tract (LUT) induces c-fos expression in ne

97 Storage and voiding of urine from the lower urinary tract (LUT) must be timed precisely to occ

98 tric burden, with many defects affecting the lower urinary tract (LUT), genital tubercle and associat

99 ciency can occur in patients with congenital lower urinary tract malformations (LUTM) even when manag

100 ociated protein 43 (GAP-43) were examined in lower urinary tract micturition reflex pathways in a chr

101 was active in anxiety, neuropathic pain, and lower urinary tract models.

102 nd Eya1 are key regulators of both upper and lower urinary tract morphogenesis.

103 Fetal lower urinary tract obstruction (LUTO) is associated wit

104 rom three unrelated families with functional lower urinary tract obstruction and secondary CAKUT.

105 uncommon but important cause of infravesical lower urinary tract obstruction that is more common in m

106 Congenital lower urinary-tract obstruction (LUTO) is caused by anat

107 taking 5-ARIs for benign conditions such as lower urinary tract [obstructive] symptoms (LUTS) may be

108 he alpha 1-AR subtype prevalent in the human lower urinary tract(pA2 values: 8.8, 10.7, 9.3, and 9.9,

109 e superseded by prevention of the underlying lower urinary tract pathology.

110 derstand how sensory disruption manifests in lower urinary tract pathophysiology.

111 Despite these bothersome lower urinary tract problems in men, conservative treatm

112 laparoscopic surgery show that this type of lower urinary tract reconstruction can be carried out us

113 Neuroplasticity of lower urinary tract reflexes after SCI may be mediated b

114 ABSTRACT: Lower urinary tract reflexes are mediated by peripheral

115 mined (L1-L2 and L6-S1) that are involved in lower urinary tract reflexes.

116 omote clearance of infecting bacteria in the lower urinary tract represents a novel function for thes

117 Lower urinary tract response to acute obstruction and me

118 embryogenesis, basonuclin 2 was detected in lower urinary-tract rudiments.

119 The lower urinary tract's virtually inevitable exposure to e

120 regulation of contractility and function, in lower urinary tract SMCs.

121 The prevalence of lower urinary tract storage disorders such as overactive

122 The main outcome was a change in a man's lower urinary tract symptom from baseline as measured by

123 Combination medical therapy improves lower urinary tract symptom in men with symptomatic beni

124 dergo surgery but scored 15-35 points on the lower urinary tract symptom questionnaire of the America

125 r who scored > or = 15 points of 35 on seven lower urinary tract symptom questions modified from the

126 From 1990 through 2000, lower urinary tract symptom severity was assessed by the

127 escribed medical therapy in the treatment of lower urinary tract symptom suggestive of benign prostat

128 ly 68% of the female nurses had at least one lower urinary tract symptom, nearly 50% had incontinence

129 eating OAB symptoms in children and men with lower urinary tract symptom.

130 management of neurogenic bladder and chronic lower urinary tract symptomatology, alpha antagonists wo

131 ing dysfunction, neurogenic bladder, chronic lower urinary tract symptomatology, idiopathic urethriti

132 Lower urinary tract symptoms (LUTS) are a common conditi

133 Lower urinary tract symptoms (LUTS) are a range of irrit

134 Lower urinary tract symptoms (LUTS) are exceptionally co

135 Lower urinary tract symptoms (LUTS) associated with beni

136 previously showed that patients with chronic lower urinary tract symptoms (LUTS) below the diagnostic

137 n prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect olde

138 Worldwide, lower urinary tract symptoms (LUTS) due to benign prosta

139 miologic studies evaluating risk factors for lower urinary tract symptoms (LUTS) have focused on Whit

140 ies in men with benign prostatic hyperplasia/lower urinary tract symptoms (LUTS) in 2014.

141 jaculation, were investigated in relation to lower urinary tract symptoms (LUTS) in a large case-cont

142 inflammation may play a role in the cause of lower urinary tract symptoms (LUTS) in older men.

143 benign prostatic hyperplasia commonly cause lower urinary tract symptoms (LUTS) in the renal transpl

144 examined the association between obesity and lower urinary tract symptoms (LUTS) in the Third Nationa

145 n is reportedly an important factor inducing lower urinary tract symptoms (LUTS) including urinary fr

146 d or acidic beverages as self-management for lower urinary tract symptoms (LUTS) is limited.

147 tatic hyperplasia (BPH) as the main cause of lower urinary tract symptoms (LUTS) may lead to acute ur

148 d women, there is an increasing incidence of lower urinary tract symptoms (LUTS) which are increasing

149 ncreases in benign prostatic enlargement and lower urinary tract symptoms (LUTS), and it is not clear

150 rrent evidence linking lifestyle factors and lower urinary tract symptoms (LUTS), and their relevance

151 - and sex-related behaviors, HIV serostatus, lower urinary tract symptoms (LUTS), behavioral disposit

152 or a role of inflammation in the etiology of lower urinary tract symptoms (LUTS), raising the possibi

153 se of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), recent epidemiologi

154 Chronic lower urinary tract symptoms (LUTS), such as urgency and

155 tic hyperplasia (BPH) in older men can cause lower urinary tract symptoms (LUTS), which are increasin

156 may contribute to the development of BPH and lower urinary tract symptoms (LUTS).

157 H) effect symptomology in men suffering from lower urinary tract symptoms (LUTS).

158 the cause of clinically significant BPH with lower urinary tract symptoms (LUTS).

159 is prevalent in old men and often results in lower urinary tract symptoms (LUTS).

160 pment of benign prostatic hyperplasia and/or lower urinary tract symptoms (LUTS).

161 e and benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

162 any patients suffer from chronic, irritative lower urinary tract symptoms (LUTS).

163 multiple sclerosis (MS) develop a variety of lower urinary tract symptoms (LUTS).

164 e varied pathophysiologic mechanisms causing lower urinary tract symptoms (LUTS).

165 rmal purinergic signaling is associated with lower urinary tract symptoms (LUTS).

166 ction therapy as an alternative treatment of lower urinary tract symptoms (LUTS).

167 ultifactorial problem that may include other lower urinary tract symptoms (LUTS).

168 matic benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

169 n prostatic hyperplasia (BPH) and associated lower urinary tract symptoms affect a large percentage o

170 How such therapies for lower urinary tract symptoms affect sexual function in m

171 e and behavioural interventions for men with lower urinary tract symptoms aim to allow the patient so

172 Lower urinary tract symptoms among female nurses should

173 study aimed to investigate the prevalence of lower urinary tract symptoms among female nurses, and th

174 From the literature, it is known that lower urinary tract symptoms and benign prostatic hyperp

175 Medical therapy for lower urinary tract symptoms and benign prostatic hyperp

176 the issue of combination medical therapy for lower urinary tract symptoms and benign prostatic hyperp

177 sy has surrounded the evaluation of men with lower urinary tract symptoms and benign prostatic obstru

178 Most of the data linking lower urinary tract symptoms and erectile dysfunction su

179 uria, have meant a shift in the way men with lower urinary tract symptoms are assessed and managed.

180 l history is a key step in assessing whether lower urinary tract symptoms are due to BPH or to some o

181 In men, lower urinary tract symptoms are most often attributed t

182 Male lower urinary tract symptoms are often attributed to ben

183 In women, lower urinary tract symptoms are often considered to res

184 y over the last decade and now most men with lower urinary tract symptoms are treated at some point w

185 Nearly all older men will experience lower urinary tract symptoms associated with benign pros

186 fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prosta

187 Lower urinary tract symptoms due to benign prostatic hyp

188 of diagnostic test accuracy among males with lower urinary tract symptoms due to bladder outlet obstr

189 aluation is the accurate characterization of lower urinary tract symptoms for the purposes of treatme

190 A substantial proportion of men with lower urinary tract symptoms have a combination of both

191 toileting behaviours exist among women, and lower urinary tract symptoms have a high prevalence and

192 Male patients with lower urinary tract symptoms have historically been mana

193 reatment of benign prostatic hyperplasia and lower urinary tract symptoms have yet to be performed.

194 mptoms and erectile dysfunction suggest that lower urinary tract symptoms impair the overall quality

195 We present a case report of AUV with lower urinary tract symptoms in a 6-year-old boy with co

196 asia (BPH) is a complex condition leading to Lower Urinary Tract Symptoms in aging men, characterized

197 tion of prostatic stents in the treatment of lower urinary tract symptoms in men secondary to benign

198 ignaling, and BSM remodeling associated with lower urinary tract symptoms in patients with BPH.

199 ore symptomatic among the cohort of men with lower urinary tract symptoms in the community.

200 ersies and developments in the evaluation of lower urinary tract symptoms in the female, and briefly

201 me guidance for the structured evaluation of lower urinary tract symptoms in the female, especially w

202 tial components of the initial evaluation of lower urinary tract symptoms in the female.

203 ed risks of benign prostatic hyperplasia and lower urinary tract symptoms include obesity, diabetes,

204 ides benefit for men with moderate to severe lower urinary tract symptoms including overactive bladde

205 The assessment of lower urinary tract symptoms is an essential component o

206 When further investigation of lower urinary tract symptoms is being considered, indivi

207 In both sexes, the etiology of lower urinary tract symptoms is multifactorial, and symp

208 ng study for the evaluation of patients with lower urinary tract symptoms is not suggested by America

209 Medical treatment of lower urinary tract symptoms is the mainstay of therapy

210 elationship between toileting behaviours and lower urinary tract symptoms is unclear.

211 Men with overactive bladder and other lower urinary tract symptoms may not respond to monother

212 is of bladder outlet obstruction in men with lower urinary tract symptoms may reduce the need for inv

213 ut only approximately two-thirds of men with lower urinary tract symptoms meet the accepted diagnosti

214 a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo.

215 l, men in seven UK hospitals with bothersome lower urinary tract symptoms or urinary retention second

216 investigate TURP versus ThuVARP in men with lower urinary tract symptoms or urinary retention second

217 1-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effe

218 Alpha1-adrenergic antagonists relieve lower urinary tract symptoms related to benign prostatic

219 ltation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms scales were used to assess

220 with prostate artery embolization (PAE) for lower urinary tract symptoms secondary to benign prostat

221 havioural programme can significantly reduce lower urinary tract symptoms severity and decrease objec

222 Men presenting with lower urinary tract symptoms should undergo comprehensiv

223 Progressive neurological disease can cause lower urinary tract symptoms similar to those seen in bl

224 Arthritis and Lower urinary tract symptoms suggestive of benign prosta

225 Men who have lower urinary tract symptoms that are consistent with be

226 th a diagnosis of BPH and moderate-to-severe lower urinary tract symptoms that were refractory to med

227 lly well tolerated therapy for patients with lower urinary tract symptoms thought to be associated wi

228 of standard benign prostatic hyperplasia and lower urinary tract symptoms treatment algorithms is pot

229 In men with lower urinary tract symptoms treatment may need to be di

230 However, lower urinary tract symptoms were not significantly asso

231 'Lower urinary tract symptoms' is a term that describes s

232 eing essential in the assessment of men with lower urinary tract symptoms, although there are no high

233 context of benign prostatic hyperplasia and lower urinary tract symptoms, analog ARF6 functions in c

234 There was an improvement in lower urinary tract symptoms, assessed by International

235 qualitative and quantitative improvements in lower urinary tract symptoms, but also in offering a day

236 gnaling decreases BPH volume and can relieve lower urinary tract symptoms, but the mechanisms of andr

237 or treatment of storage symptoms in men with lower urinary tract symptoms, combinations of antimuscar

238 st-effective and accurate analysis of female lower urinary tract symptoms, existing technology must b

239 , post-menopausal bleeding, rectal bleeding, lower urinary tract symptoms, haematuria, change in bowe

240 blockers can be useful for treatment of male lower urinary tract symptoms, including the overactive b

241 nic obstructive pulmonary disease, glaucoma, lower urinary tract symptoms, non-ST-segment elevation m

242 sultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms, or ICIQ-MLUTS, and the Int

243 s the participants' toileting behaviours and lower urinary tract symptoms, respectively.

244 c hyperplasia, sexually transmitted disease, lower urinary tract symptoms, stress, and reduced sunlig

245 drawn from a general population of men with lower urinary tract symptoms, the calculations of incide

246 Among males with lower urinary tract symptoms, the likelihood ratios (LRs

247 In patients with lower urinary tract symptoms, the symptoms alone are not

248 etiologies may exist in the individual with lower urinary tract symptoms, treatment may fail as a re

249 nd prostate cancer are often associated with lower urinary tract symptoms, which can severely affect

250 ostate hyperplasia (BPH) is a major cause of lower urinary tract symptoms, with an increased volume o

251 perative to accurately define terminology of lower urinary tract symptoms.

252 reatment of benign prostatic hyperplasia and lower urinary tract symptoms.

253 ed to use of other medications indicated for lower urinary tract symptoms.

254 evaluated anticholinergic drugs in men with lower urinary tract symptoms.

255 ness and safety of anticholinergics for male lower urinary tract symptoms.

256 stress incontinence without increasing other lower urinary tract symptoms.

257 gies (self-management) available to men with lower urinary tract symptoms.

258 mary aim of investigation for a patient with lower urinary tract symptoms.

259 e using phages has therapeutic potential for lower urinary tract symptoms.

260 ary evaluation of the female presenting with lower urinary tract symptoms.

261 reatment of benign prostatic hyperplasia and lower urinary tract symptoms.

262 ition zone of the prostate gland, leading to lower urinary tract symptoms.

263 ation and progression of clinically relevant lower urinary tract symptoms.

264 recapitulate several clinical components of lower urinary tract symptoms.

265 urinary tract infection was associated with lower urinary tract symptoms.

266 nificantly associated with susceptibility to lower urinary tract symptoms.

267 association between toileting behaviours and lower urinary tract symptoms.

268 association between toileting behaviours and lower urinary tract symptoms.

269 trual period were negatively associated with lower urinary tract symptoms.

270 n delivery had a protective association with lower urinary tract symptoms.

271 hyperplasia with good long-term results for lower urinary tract symptoms.

272 ing to void) were positively associated with lower urinary tract symptoms.

273 is one of the most common and bothersome of lower urinary tract symptoms.

274 tive as alpha1-adrenoceptor blockers in male lower urinary tract symptoms.

275 of bladder outlet obstruction in males with lower urinary tract symptoms.

276 ta regarding the incidence and prevalence of lower urinary tract symptoms/benign prostatic hyperplasi

277 cy of anticholinergic medication in men with lower urinary tract symptoms/benign prostatic hyperplasi

278 es of anticholinergic medication in men with lower urinary tract symptoms/benign prostatic hyperplasi

279 of drugs currently used for the treatment of lower urinary tract symptoms/overactive bladder syndrome

280 dder dysfunction, including incontinence and lower urinary tract symptoms; with the causes remaining

281 ncontrolled congestive heart failure, severe lower-urinary-tract symptoms, and erythrocytosis.

282 IBCs were associated with lower urinary tract syndrome (OR, 3.6; 95% CI, 1.1-11.8;

283 Overactive bladder is an important lower urinary tract syndrome that negatively affects the

284 icrosatellite instability occur in upper and lower urinary tract TCC, suggesting biologic differences

285 er and urethra in regulating reflexes in the lower urinary tract that depend on the state of the blad

286 act [the nephric duct (ND)] with that of the lower urinary tract (the cloaca).

287 le urethral sensory information plays in the lower urinary tract, the relationship between physiologi

288 sensory feedback plays in regulation of the lower urinary tract, there is little information about t

289 e alpha(1A) receptor being most prevalent in lower urinary tract tissue.

290 f the mechanosensitive ion channel PIEZO2 in lower urinary tract tissues, where it is required for lo

291 c renal transplantation into a dysfunctional lower urinary tract to evaluate the results of contempor

292 renergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagoni

293 ature is replete with studies involving male lower urinary tract trauma, however the diagnosis and ma

294 es in the diagnosis and management of female lower urinary tract trauma.

295 There were 23 upper and 61 lower urinary tract tumors confirmed in 15 and 32 patien

296 etection rate than the EP for both upper and lower urinary tract tumors, which suggests its possible

297 mooth muscle, and mesenchyme surrounding the lower urinary tract (via the Pax3-Cre transgene) resulte

298 A variety of fistulas occur involving the lower urinary tract with adjacent organs namely the vagi

299 ces in molecular embryology of the upper and lower urinary tract with an emphasis on clinical correla

300 c renal transplantation into a dysfunctional lower urinary tract yields outcomes comparable to transp